Patients taking the analgesic tramadol have an increased propensity for hypoglycemia compared to other opioids, according to a new analysis of the Food and Drug Administration’s Adverse Event Reporting Systems.
For many Muslims, fasting is an important part of individual and community life. Healthcare professionals should adopt a patient-centered approach to diabetes care during Ramadan.
A predictive model is presented for hypoglycemia that combines nearly all known and readily assessed risk factors for hypoglycemia such as infection, non-long-acting insulin, and dementia.
Intensive glucose-lowering therapy is prevalent among U.S. adults with diabetes and results in hospitalizations and emergency department visits for hypoglycemia.
Diabetes self-management education and support can cut hypoglycemia risk.
The Food and Drug Administration (FDA) has approved Baqsimi (glucagon; Eli Lilly) nasal powder for the treatment of severe hypoglycemia in patients with diabetes aged 4 years and older.
FDA has granted Breakthrough Therapy designation to avexitide (Eiger Biopharmaceuticals) for the treatment of post-bariatric hypoglycemia (PBH).
If approved, it would be the first room temperature stable liquid glucagon in an autoinjector formulation.
Dasiglucagon was found to be an effective and safe treatment option for severe hypoglycemia in type 1 diabetes.
For patients with diabetes who are hospitalized, hypoglycemia or near-normal glucose values during the last 24 hours of hospitalization can lead to higher rates of 30-day readmission and mortality.
